Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Autor:	Jong Yeob Kim, Joo Hyung Lee, Seungeun Lee, Donggun Lee, Jeonghyun Kang, Ji Hyun Noh, Haejun Lee, Jin Woon Jeong, Na Won Kim
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty Univariate analysis business.industry overall survival Hazard ratio Cancer Review General Medicine medicine.disease sarcopenia immune checkpoint inhibitors Clinical trial hazard ratio Internal medicine Sarcopenia Meta-analysis medicine Medicine Biomarker (medicine) Progression-free survival business progression-free survival
Zdroj:	Journal of Clinical Medicine, Vol 10, Iss 5329, p 5329 (2021) Journal of Clinical Medicine
ISSN:	2077-0383
DOI:	10.3390/jcm10225329
Popis:	Background: Although sarcopenia has been reported to predict survival in cancer patients, its impact on patients who received immune checkpoint inhibitors (ICIs) has not been thoroughly investigated. This systematic review aimed to assess the long-term oncologic impact of sarcopenia on patients who received ICIs. Methods: A systematic review of studies indexed in the PubMed, Embase, and Cochrane databases, up to April 1, 2021, was conducted. Studies that reported hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) based on sarcopenia in patients treated with ICIs were included. The inverse variance method was used with a random-effects model for data analysis. Results: A total of 1284 patients from 14 studies were included. Among the patients who received ICIs, patients with sarcopenia had a significant increase in overall mortality compared to patients without sarcopenia in univariate analyses (HR = 1.66, 95% CI = 1.20–2.29, p = 0.002) and in adjusted HRs (HR = 1.55, 95% CI = 1.15–2.10, p = 0.004). The same results were obtained for PFS by both univariate analysis (HR = 1.75, 95% CI = 1.37–2.23, p < 0.001) and adjusted HRs (HR = 1.63, 95% CI 1.28–2.09, p < 0.001). Conclusions: Sarcopenia appears to be an effective biomarker for predicting long-term oncologic outcomes in patients receiving ICI therapy and hence plays an important role when making treatment decisions. However, the fundamental role of this association with survival should be further investigated in large cohorts and clinical trials.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de8bd6c30cdfb953e81c68f5886f937e https://doi.org/10.3390/jcm10225329 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.